How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

October 16, 2015

Melanoma in Personalized Medicine and Biomarkers

Dr. Sanjiv Agarwala talks about the importance of personalizing melanoma care, focusing on where the industry currently stands and what’s in store for the future of targeted therapies and immunotherapies.

January 4, 2017

Serotonin and Carcinoid Tumors

Hal Gerstein, MD, details this neurotransmitter’s role in the development of carcinoid tumors and carcinoid syndrome.